EP1037610A4 - Liposomal camptothecin formulations - Google Patents

Liposomal camptothecin formulations

Info

Publication number
EP1037610A4
EP1037610A4 EP98946983A EP98946983A EP1037610A4 EP 1037610 A4 EP1037610 A4 EP 1037610A4 EP 98946983 A EP98946983 A EP 98946983A EP 98946983 A EP98946983 A EP 98946983A EP 1037610 A4 EP1037610 A4 EP 1037610A4
Authority
EP
European Patent Office
Prior art keywords
liposomal camptothecin
camptothecin formulations
formulations
liposomal
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98946983A
Other languages
German (de)
French (fr)
Other versions
EP1037610A1 (en
Inventor
Karen Lewis Moynihan
David Lloyd Emerson
Su-Ming Chiang
Ning Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSI Pharmaceuticals LLC filed Critical OSI Pharmaceuticals LLC
Publication of EP1037610A1 publication Critical patent/EP1037610A1/en
Publication of EP1037610A4 publication Critical patent/EP1037610A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98946983A 1997-09-16 1998-09-15 Liposomal camptothecin formulations Withdrawn EP1037610A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5908397P 1997-09-16 1997-09-16
US59083P 1997-09-16
PCT/US1998/019086 WO1999013816A2 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations

Publications (2)

Publication Number Publication Date
EP1037610A1 EP1037610A1 (en) 2000-09-27
EP1037610A4 true EP1037610A4 (en) 2004-07-07

Family

ID=22020747

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98946983A Withdrawn EP1037610A4 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations

Country Status (8)

Country Link
EP (1) EP1037610A4 (en)
JP (1) JP2003510239A (en)
KR (1) KR100711315B1 (en)
AU (1) AU751439B2 (en)
BR (1) BR9812316A (en)
CA (1) CA2303366A1 (en)
NZ (1) NZ503293A (en)
WO (1) WO1999013816A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527466A (en) * 1998-09-16 2002-08-27 アルザ・コーポレーション Liposome-confined topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
IL153676A0 (en) 2000-06-30 2003-07-06 Inex Pharmaceuticals Corp Liposomal pharmaceutical compositions
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
IL155696A0 (en) * 2000-11-09 2003-11-23 Neopharm Inc Sn-38 lipid complexes and methods of use
DE10157994A1 (en) * 2001-05-25 2003-01-02 G O T Therapeutics Gmbh Liposomally encapsulated hydrophobic active ingredients with a high active ingredient content> 50% and methods for producing pharmaceutical preparations which comprise liposomally encapsulated hydrophobic active ingredients
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
AU2003249882B2 (en) * 2002-06-26 2008-09-18 Medigene Ag Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
US20040170677A1 (en) * 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
CA2584279C (en) * 2004-11-05 2015-01-27 Index Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
CN101209243B (en) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
TWI428135B (en) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
KR101130754B1 (en) 2010-06-25 2012-03-28 제일약품주식회사 Pharmaceutical compositions having improved solubility of poorly soluble tricyclic derivative compounds
AU2013203682B2 (en) * 2011-08-25 2016-03-31 Trophos Liposome comprising at least one cholesterol derivative
FR2979239A1 (en) * 2011-08-25 2013-03-01 Trophos LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE
WO2014047116A1 (en) * 2012-09-18 2014-03-27 Comfort Care For Animals Llc Encapsulating liposomes
MX2015005992A (en) 2012-11-20 2016-03-07 Spectrum Pharmaceuticals Inc Improved method for the preparation of liposome encapsulated vincristine for therapeutic use.
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
KR102162351B1 (en) 2018-11-08 2020-10-06 순천향대학교 산학협력단 Drug-conjugated compound and uses thereof
CN116327701A (en) * 2023-02-27 2023-06-27 北京大学深圳医院（北京大学深圳临床医学院） Composite nano liposome for treating hepatic fibrosis and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008986A1 (en) * 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008986A1 (en) * 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURKE T G ET AL: "STABILIZATION OF TOPOTECAN IN LOW PH LIPOSOMES COMPOSED OF DISTEAROYLPHOSPHATIDYLCHOLINE", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 83, no. 7, 1 July 1994 (1994-07-01), pages 967 - 969, XP000454801, ISSN: 0022-3549 *
CULLIS PR, MAYER LD, BALLY MB, MADDEN TD, HOPE MJ: "Generating and loading of liposomal systems for drug-delivery applications", ADVANCED DRUG DELIVERY REVIEWS, vol. 3, 1989, pages 267 - 282, XP002279310 *
DAOUD S S ET AL: "ANTITUMOR EFFECT OF LIPOSOME-INCORPORATED CAMPTOTHECIN IN HUMAN MALIGNANT XENOGRAFTS", ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 6, no. 1, 1995, pages 83 - 93, XP000878680, ISSN: 0959-4973 *
See also references of WO9913816A3 *
SUGARMAN S ET AL: "LIPOSOMAL CAMPTOTHECIN: FORMULATION AND CYTOTOXICITY AGAINST KB CELLS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. ORLANDO, MAY 19 - 22, 1993, PHILADELPHIA, AACR, US, vol. MEETING 84, 1 March 1993 (1993-03-01), pages 422, XP000578376, ISSN: 0197-016X *

Also Published As

Publication number Publication date
AU751439B2 (en) 2002-08-15
AU9387798A (en) 1999-04-05
KR100711315B1 (en) 2007-04-27
WO1999013816A3 (en) 2001-11-01
WO1999013816A2 (en) 1999-03-25
BR9812316A (en) 2001-03-20
KR20010030599A (en) 2001-04-16
NZ503293A (en) 2002-09-27
CA2303366A1 (en) 1999-03-25
JP2003510239A (en) 2003-03-18
EP1037610A1 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
GB9715751D0 (en) Formulations
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
EP1020193A4 (en) Oral preparation
EP1037610A4 (en) Liposomal camptothecin formulations
GB9713149D0 (en) Pharmaceutical formulations
GB2323531B (en) Therapeutic formulations
ZA9811461B (en) New formulation
PL335700A1 (en) Novel preparation
PL337970A1 (en) Novel preparation
GB9715490D0 (en) Pharmaceutical preparation
EP0907644A4 (en) Pharmaceutical preparation
ZA982073B (en) Pharmaceutical preparation
GB9724544D0 (en) Novel Formulation
GB9725061D0 (en) Revitalisation formulation
GB9706957D0 (en) Formulation
IL126664A0 (en) Explosive formulations
IL126663A0 (en) Explosive formulations
IL126669A0 (en) Explosive formulations
GB2316869B (en) An antihaemolytic liposomal preparation
IL126665A0 (en) Explosive formulations
GB9704521D0 (en) Formulations
GB9703101D0 (en) Formulations
GB9703100D0 (en) Formulations
GB9703099D0 (en) Formulations
PL322663A1 (en) Dispergating preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000417

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000417;LT PAYMENT 20000417;LV PAYMENT 20000417;MK PAYMENT 20000417;RO PAYMENT 20000417;SI PAYMENT 20000417

D17D Deferred search report published (deleted)
D17D Deferred search report published (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OSI PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/4745 B

Ipc: 7A 61K 9/127 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040526

17Q First examination report despatched

Effective date: 20040827

17Q First examination report despatched

Effective date: 20040827

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091006

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1031103

Country of ref document: HK